

11/27/2007

**CURRICULUM VITAE**  
**THOMAS WISNIEWSKI**

*Current Appointment and Address:* Professor of Neurology, Pathology and Psychiatry  
New York University School of Medicine  
550 First Ave., Millhauser Laboratory, Rm HN 419  
New York, N.Y., 10016

*Telephone Number:* 212-263-7993

*Fax:* 212-263-7528

*e-mail:* [thomas.wisniewski@med.nyu.edu](mailto:thomas.wisniewski@med.nyu.edu)

*Web Site:* <http://www.med.nyu.edu/people/wisnit01.html>

*Place of birth:* Gdansk, Poland

*Citizenship:* USA

**Education:**

1980 BS University of London, King's College, London, England  
1983 MBBS (MD) King's College Medical School, London, England

**Postdoctoral Training:**

Internships and Residencies:

1983-1984 Rotating internship in Medicine and Surgery at King's College and West Hill Hospitals, London, England

1984-1985 Resident in Anatomical Pathology, Downstate Medical Center, Brooklyn, New York

1985-1987 Resident of Neurology, New York University Medical Center, New York

1987-1988 Chief Resident of Neurology, New York University Medical Center, New York

1988-1989 Clinical Fellow in Neuropathology, Columbia-Presbyterian Medical Center, Columbia University, New York

1989-1990 Chief Resident of Neuropathology, Columbia-Presbyterian Medical Center, Columbia University, New York

**Licensure and Certification:**

1984 Certificate of Full Registration as a Medical Practitioner, England

1985 New York State License Registration

1989 American Board of Psychiatry and Neurology Certificate in Neurology

1990 American Board of Pathology Certificate in Neuropathology

**Academic Appointments:**

1987-1988 Assistant Clinical Instructor in Neurology, New York University

1988-1990 Clinical Fellow in Neuropathology, Columbia University, New York

1990-1992	Clinical Instructor in Neurology, New York University
1992-1998	Assistant Professor of Neurology and Pathology, New York University
1997-	Director of the Neuropathology Core of the New York University Alzheimer's Disease Center
1997-	Director of the Conformational Disorders Laboratory, NYU
1998-1999	Associate Professor of Neurology and Pathology, New York University
1999-2005	Associate Professor of Neurology, Pathology and Psychiatry (tenured), New York University
2005-	Professor of Neurology, Pathology and Psychiatry (tenured), New York University

Hospital Appointments:

1990-1993	Instructor in Neurology, Bellevue Hospital, New York
1993-1998	Assistant Attending in Neurology, Bellevue Hospital, New York
1998-	Associate Attending in Neurology, Bellevue Hospital, New York
1990-	Staff Neurologist Manhattan Veterans Administration Hospital, New York

Major Committee Assignments:

## National and Regional:

1992-present	Ad Hoc Committee of Reviewers, Annals of Neurology
1992-present	Ad Hoc Committee of Reviewers, American Journal of Pathology
1995	Program Committee for the American Association of Neuropathology
1995-96	Ad Hoc Neurological Sciences-1 Study Section Committee Member, NIH
1996	Neuroscience of Aging Study Section Committee Member, NIH
1997	Ad Hoc NIH Program Project Study Section Review Committee Member
1998	NIH side-visit of Program Project, University of Southern Alabama
1998	NIH reverse side-visit of Prusiner Program Project, University of California
1998-9	NIH Cellular and Molecular Developmental Neurosciences-2 Ad Hoc Study Section Committee Member
1999-2003	NIH Brain Disorders and Clinical Neurosciences-4 (BDCN-4) Ad hoc study section member.
1999-present	Reviewer for the American Federation of Aging Research
2003	Reviewer for the Department of Defense National Prion Research Initiative
2003-present	Permanent Study Section Committee Member, National Institutes

2005- present	of Health, BDCN-4 (now known as Clinical Neuroimmunology and Brain Tumors; CNBT 01, SRA: Jay Joshi) Permanent Study Section committee member, National Institutes of Health, NIA-N (Neuroscience of Aging) Study Section, term of committee membership: July 1, 2005 to June 30, 2009
2006	Member of the Scientific Program Committee of the 11th International Conference on Alzheimer's Disease and Related Disorders

NIH Alzheimer's Disease Research Center and Program Project Site-Visit Committee Member :

Nov., 1993	NIH reviewer of Massachusetts Alzheimer's Disease Research Center
Feb., 1994	NIH reviewer of the University of Southern California Alzheimer's Research Center
Sept., 1994	NIH reviewer of the University of Washington, St. Louis Alzheimer's Disease Research Center
Jan., 1996	NIH reverse site-visit of Alzheimer's Disease Research Centers
March, 1999	NIH site-visit reviewer of Alzheimer's Program Project at USC
Feb, 2000	NIH site-visit reviewer of Program Project at the Univ. of S. Alabama
March, 2000	NIH site-visit reviewer of Program Project at Univ. Cal, Irvine
Oct. 2000	NIH site visit reviewer of Program Project at Univ. Cal, Irvine
Jan, 2001	Member of NIA ADCC grant applications (ZAG1 PCR-5) study section
April, 2003	Member of the NIH Review Committee for the Mt. Sinai Medical Center Alzheimer's Disease Research Center
March, 2004	Member of the NIH Review Committee for the Mt. Sinai Medical Center Alzheimer's Disease Program Project
March, 2004	Member of the NIH Review Committee for the John Hopkins University Alzheimer's Disease Program Project
June, 2004	Member of the NIH Review Committee for the University of Philadelphia Program Project (PI Virginia Lee, P01 AG017586-06, Frontotemporal Dementias: Genotypes and Phenotypes).
2004-present	Member of External Advisor Panel for the Mt. Sinai Alzheimer's Disease Research Center
2005-present	Member of the External Advisor Panel for the University of South Florida Alzheimer's Disease Research Center

**Awards:**

1999	Zenith Award from the Alzheimer's Disease Association
2002	Alzheimer Award from <i>The Journal of Alzheimer's Disease</i> (for the best publication in their Journal for the year).

**Membership in Professional Societies:**

1982-	British Medical Association
1984-	American Medical Association
1987-	American Academy of Neurology
1989-	American Association of Neuropathology
1996-	Society for Neuroscience
1997-	The Harvey Society

**Editorial Boards:**

1997-2002	Editor, Amyloid
1998-2001	Editor, Journal of Neuropathology and Experimental Neurology
2000-2001	Editor, Journal of Alzheimer's Disease
2001-2002	Senior Editor, Journal of Alzheimer's Disease
2002-2005	Editorial Board Acta Neuropathologica
2004-	Associate Editor Current Alzheimer Research

**Major Research Interests:**

1. The pathogenesis and treatment of Alzheimer's Disease.
2. Treatment approaches for the prion diseases.
3. Development of novel amyloid imaging methods.
4. The biochemistry and molecular biology of other cerebral amyloidoses.

**Principal Clinical and Hospital Service Responsibilities:**

1990-	Attending Physician, Bellevue Hospital, New York (serve as the Neurology Attending on the general Neurology Ward 1-2 months/year)
1990-	Attending Physician Neurology Department, Tisch Hospital (NYU Med. Cent.)
1990-	Neurology Consult Attending Physician, Manhattan Veterans Administration Hospital, New York (serve as the Consult Neurology Attending for general Neurology on a part time basis year round and run a Dementia clinic once/week).
2005-	Director of Memory Disorders Center, NYU Medical Center
2006-	Neuropathology Fellowship Program Director, NYU Medical Center

**Teaching Experience:**

1984-1985	Organized lectures in General Pathology, Downstate Medical Center, Brooklyn, New York
1987-1988	Lecture Organizer in General Neurology, New York University Medical Center
1988-1990	Course developer and lecturer in Neuropathology, Columbia-Presbyterian Medical Center, New York

- 1990-present Clinical Lecturer in Neurology Course, New York University Sch. Med.
- 1998-present Lecturer and Organizer of Neuropathology Course, NYU Sch. Med.
- 1999-present Lecturer in Molecular Signaling and Drug Development Course, NYU Sch. Med.
- 1999-present Lecturer in Neurogenetics Course, NYU Sch. Med.
- 1999-present Lecturer in Pathology Board Review course (Neuropathology), NYU Sch. Med.
- 2000- Lecturer in Psychiatry Board Review course, NYU Sch. Med.
- 2006-present Director of Neuropathology Fellowship, NYU Sch. Med.

### **Grant Support:**

#### **Principal Investigator:**

- 1991-1994 Alzheimer's Disease Association, Clinical Investigator Initiated Award Grant (IIRG91-102): The Lewy body Variant of Alzheimer's disease
- 1992-1997 PI of National Institute of Health (National Institute of Aging) Clinical Investigator Award (K08-AG00542-01): Lewy Body Disease and Gelsolin
- 1992-1993 New York University Medical Center Alzheimer's Disease Center Pilot Study: The Source of Alzheimer's Amyloid Protein.
- 1995-1996 New York University Medical Center Alzheimer's Disease Center Pilot Study: Alzheimer's disease and Amyloid  $\beta$  Fibrillogenesis.
- 1995-1996 National Institute of Health (National Institute of Aging) Pilot Study in LEAD award. Theoretical molecular modeling of amyloid  $\beta$ .
- 1997-1998 PI of National Center for Research Resources, National Institute of Health. Shared Instrumentation Grant. FTS-6000 Spectrometer Mainframe
- 1997-1998 National Institute of Health (National Institute of Aging) Pilot Study in LEAD award (AG10953) The Biochemistry of Human Prion Strains.
- 1998-2001 Alzheimer's Disease Association, Investigator Initiated Award: Imaging of Alzheimer's disease lesions *in vivo* (IIRG-98-017)
- 1999-2001 Alzheimer's Disease Association, Zenith Award: Amyloid  $\beta$  and Apolipoprotein E Interactions in Vivo and *in Vitro* (Zenith-99-1791).
- 2000-2005 PI of the Neuropathology Core on NIH Program Project (PO1AG17617): In Vivo Models of Neuronal and Vascular Pathobiology in AD (PI of Program Project is Dr. Ralph Nixon)
- 2000-2004 PI of Project 3 (The role of ischemia and vascular pathology in Alzheimer's disease) on NIH Program Project (PO1AG17617): In Vivo Models of Neuronal and Vascular Pathobiology in AD
- 2000-2002 American Parkinson Disease Association Investigator Grant: Biochemistry and Immunohistochemistry of Lewy Bodies.
- 2002-2005 Alzheimer's Disease Association, Investigator Initiated Research Award: Vaccine Therapy for the Prevention and Treatment of Prion Disease (IIRG-02-3702)
- 2000-2010 Director of the Neuropathology Core of the NYU Alzheimer's Disease Clinical Center (NIH NIA AG08051)

- 1999-2010 PI of National Institute of Health (NIA) R01 Amyloid  $\beta$  peptide and apolipoprotein E AG15408
- 2002-2012 PI of NIA/NIH R01 grant: Detection and Clearance of AD Amyloid Lesions. AG20245,
- 2004-2009 PI of NINDS/NIH R01 grant: Therapeutic Approaches for Prion Disease, NS047433
- 2005-2008 PI of NIH Fogarty International Research Collaborative Award, (R03 TW006848): Therapy for Alzheimer and Prion diseases.
- 2006-2009 Alzheimer's Disease Association, Investigator Initiated Research Award: Mucosal Immunization Therapy in Alzheimer's Disease Mice (IRG-06-26434)
- 2007-2009 PI of NIH/NIA/Fogarty International Center R21 grant (R21 AG028187) Immunization Approaches for Alzheimer's Disease.

**Co- Investigator:**

- 1995-1999 National Institute of Health (National Institute of Aging) (R01 AG08721-04): Amyloid Angiopathy, Early Plaque and Aging
- 1999-2004 National Institute of Health (R01 AR02594): Conformational Disorders: Amyloid and Prion Proteins

**Patents:**

- 1) Synthetic Immunogenic but Non-Amyloidogenic Peptides Homologous to Amyloid  $\beta$  for Induction of an Immune Response to Amyloid  $\beta$  and Amyloid Deposits; **Wisniewski T**, Frangione B, Sigurdsson E. Filed 5/22/2000
- 2) Detection of Alzheimer's Amyloid by Magnetic Resonance Imaging; **Wisniewski T**, Sigurdsson, E, Zaim Y, Turnbull D. Filed 5/23/2001
- 3) Synthetic Immunogenic but Non-Deposit-Forming Polypeptides and Peptides Homologous to Amyloid  $\beta$ , Prion Protein, Amylin,  $\alpha$ -Synuclein or Polyglutamine Repeats for Induction of an Immune Response Thereto. **Wisniewski T.**, Sigurdsson E, Frangione B. Filed 11/21/2001
- 4) Mucosal Immunization as a vaccine to prevent prion infection. **Wisniewski T**, Sigurdsson E, Chabalgoity JA, Goni F. Filed 3/2004
- 5) Inhibition of amyloid- $\beta$  deposition in Alzheimer's disease patients by blocking the binding between amyloid- $\beta$  and pathological chaperones. **Wisniewski T**, Sadowski M. Filed 3/2003.
- 6) Diagnostic Imaging Method for the Detection of Prion Amyloid. **Wisniewski T**, Sadowski M, Mathis CA., Klunk WE. Filed 2/2004.

**Bibliography:**

Peer Reviewed Journal Publications (Abstracts are not listed. Reviews and book chapters listed separately.):

1. Moon HM, **Wisniewski T**, Mertz P, DeMartini J, Wisniewski HM. Purification of neurofilament subunits from bovine brains and studies on neurofilament assembly. *Journal of Cell Biology* 1981; 89:560-567.
2. Kitaguchi T, Wisniewski KE, Maslinska S, Maslinska D, **Wisniewski TM**.  $\beta$ -Amyloid immunoreactivity in patients with neuronal ceroid lipofuscinosis: ultrastructural and biochemical demonstration. *Neuroscience Letters* 1990; 112:155-160.
3. Onesti S, **Wisniewski T**, Post K. Clinical versus subclinical pituitary apoplexy: presentation, surgical management and outcome in 21 patients. *Neurosurgery* 1990; 26:980-986.
4. Onesti S, **Wisniewski T**, Post K. Pituitary apoplexy associated with a Rathke's cleft cyst. *Neurosurgery* 1990; 27:644-646.
5. **Wisniewski T**, Sisti M, Inhirami G, Knowles D, Powers J. Solitary intracranial plasmacytoma: immunohistochemical and molecular studies. *Neurosurgery* 1990; 27:826-829.
6. Kitaguchi T, Wisniewski KE, Maslinski S, Maslinska D, **Wisniewski TM**, Kim KS. Beta-protein immunoreactivity in brains of patients with neuronal ceroid lipofuscinosis: ultrastructural and biochemical demonstration. *Neuroscience Letters* 1990, 112:155-160.
7. **Wisniewski T**, Haltia M, Ghiso J, Frangione B. Lewy bodies are immunoreactive with antibodies raised to gelsolin related amyloid. *American Journal of Pathology* 1991; 138:1077-1083.
8. Castano EM, **Wisniewski T**, Frangione B. Inherited amyloids of the nervous system. *Current Opinion in Neurobiology* 1991; 1:448-454.
9. Haltia M, Ghiso J, Miller D, Frangione B, **Wisniewski T**. Gelsolin variant and  $\beta$ -amyloid co-occur in a case of Finnish amyloidosis and Alzheimer's. *Neurobiology of Aging* 1991; 12:313-316.
10. **Wisniewski T**, Ghiso J, Frangione B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. *Biochemical and Biophysical Research*

*Communications* 1991; 179:1247-1254.

11. Constantinidis J, **Wisniewski TM**. The dominant form of the pigmentary orthochromatic leukodystrophy. *Acta Neuropathologica* 1991; 82:483-487.
12. **Wisniewski T**, Haltia M, Ghiso J, Frangione B. Lewy bodies and gelsolin. *Parkinson/Alzheimer Digest* 1992; 1:6-8.
13. Iwaki T, **Wisniewski T**, Iwaki A, Corbin E, Tomokane N, Tateishi J, Goldman JE. Accumulation of  $\alpha$ B-crystallin in central nervous system glia and neurons in pathological conditions. *American Journal of Pathology* 1992; 140:345-356.
14. Ghiso J, **Wisniewski T**, Vidal R, Rostagno A, Frangione B. Epitope mapping of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease. *The Biochemical Journal* 1992; 282:517-522.
15. **Wisniewski T**, Frangione B. Apolipoprotein E: a pathological chaperone in systemic and cerebral amyloidoses. *Neuroscience Letters* 1992; 135:235-238.
16. Constantinidis J, Wisniewski KE, **Wisniewski TM**. Senile neuronal ceroid lipofuscinosis, a report of three cases and a review of the literature. *Acta Neuropathologica* 1992; 83:461-468.
17. **Wisniewski T**, Frangione B. Molecular biology of the Dutch variant of Alzheimer's disease. *Molecular Biology* 1992; 6:75-86.
18. Rodrigues M, Rajagopalan S, Jones K, Nirankari V, **Wisniewski T**, Frangione B, Gorevic P. Gelsolin immunoreactivity in corneal amyloid, macular and granular dystrophies and wound healing. *American Journal of Ophthalmology* 1993; 115:644-652.
19. **Wisniewski T**, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble  $\beta$ -amyloid. *Biochemical Biophysical Research Communications* 1993; 192:359-365.
20. Ghiso J, Matsubara E, Koudinov A, **Wisniewski T**, Frangione B. Alzheimer's amyloid  $\beta$  specifically binds SP40,40 (Apolipoprotein J), an inhibitor of the complement membrane attack complex. *The Biochemical Journal* 1993; 293:27-30.
21. **Wisniewski T**, Castano E, Ghiso J, Frangione B. Cerebrospinal fluid inhibits fibrillogenesis by Alzheimer's disease peptides. *Annals of Neurology* 1993; 34: 631-633.

22. **Wisniewski T**, Ghiso J, Frangione B. Alzheimer's disease and soluble A $\beta$ . *Neurobiology of Aging* 1994; 15:143-152.
23. **Wisniewski T**, Lalowski M., Levy E., Marques M.R.F., Frangione B. The amino acid sequence of neuritic plaque amyloid from a familial Alzheimer's disease patient. *Annals of Neurology* 1994; 35:245-246.
24. Kida E, Golabek A, **Wisniewski T**, Wisniewski K. Regional differences of Apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain. *Neuroscience Letters* 1994; 167: 73-76.
25. Sanan DA, Weisgraber KH, Mahley RW, Huang D, Saunders A, Schmechel D, **Wisniewski T**, Frangione B, Roses A, Strittmatter WJ. Apolipoprotein E associates with  $\beta$  Amyloid peptide of Alzheimer's Disease to form novel monofibrils: Isoform Apo E4 associates more efficiently than Apo E3. *Journal of Clinical Investigation* 1994; 94:860-869.
26. Gallo G, **Wisniewski T**, Choi-Miura N, Ghiso J, Frangione B. Potential role of Apolipoprotein E in fibrillogenesis. *American Journal of Pathology* 1994; 145:1-5.
27. **Wisniewski T**, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. *American Journal of Pathology* 1994; 145:1030-1035.
28. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, **Wisniewski T**, McComb G, Frangione B, Ghiso J. Brain uptake of circulating apolipoprotein J and E complexed to Alzheimer's amyloid  $\beta$ . *Biochemical Biophysical Research Communications* 1994; 205:1431-1437.
29. **Wisniewski T**, Morelli L, Wegiel J, Levy E, Wisniewski HM, Frangione B. The influence of apolipoprotein E isotype on Alzheimer's disease pathology in 40 cases of Down's syndrome. *Annals of Neurology* 1995; 36:137-139.
30. Mangone C, Castano E, Levy E, Abiusi G, **Wisniewski T**, Marques M, Faccio E, Gorelick P, Frangione B, Sica R. Early onset Alzheimer's disease in a South American pedigree. Clinical, SPECT, immunohistochemical and DNA findings. *Acta Neurologica Scandinavica* 1995; 91:6-13.
31. Ghiso J, Plant GT, Revesz T, **Wisniewski T**, Frangione B. Familial cerebral angiopathy (British type) with nonneuritic amyloid plaque formation may be due to a novel amyloid protein. *Journal of Neurological Sciences* 1995; 129: 74-7.

32. Castano EM, Prelli F, **Wisniewski T**, Golabek A, Kumar RA, Soto C, Frangione B. Fibrillogenesis of Alzheimer's Amyloid  $\beta$  peptides and apolipoprotein E. *Biochemical Journal* 1995; 306:599-60.
33. Golabek A, Marques MA, Lalowski M, **Wisniewski T**. Alzheimer's Disease amyloid binding proteins in vitro and in normal human cerebrospinal fluid. *Neuroscience Letters* 1995; 191:79-82.
34. **Wisniewski T**, Golabek AA, Kida E, Wisniewski KE, Frangione B. Conformational mimicry in Alzheimer's disease. *American Journal of Pathology* 1995; 147:238-244.
35. **Wisniewski T**, Lalowski M, Golabek A, Frangione B. Alzheimer's Disease: An apolipoprotein E amyloidosis? *The Lancet* 1995; 345: 956-958.
36. **Wisniewski T**, Frangione B. Amyloidosis in Alzheimer's disease. *The Lancet* 1995; 346: 441.
37. **Wisniewski T**, Palha JA, Ghiso J, Frangione B. S182 protein in Alzheimer's disease neuritic plaques. *The Lancet*, 1995 346:1366.
38. **Wisniewski T**, Lalowski M, Bobik M, Russell M, Strosznajder J, Frangione B. Amyloid  $\beta$  1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. *Biochemical Journal* 1996; 313: 575-580.
39. **Article Featured on Cover:** Vidal R, Garzuly F, Budka H, Lalowski M, Linke RP, Brittig F, Frangione B, **Wisniewski T**. Meningovascular amyloidosis associated with a novel transthyretin (TTR) missense mutation at codon 18 (TTRD18G). *American Journal of Pathology* 1996;148: 361-366.
40. **Wisniewski T**, Lalowski M, Baumann M, Rauvala H, Raulo E, Nolo R, Frangione B. HB-GAM is a cytokine present in Alzheimer's and Down's Syndrome Lesions. *Neuroreport* 1996; 7: 667-671.
41. Baumann MH, **Wisniewski T**, Plant GT, Levy E, Ghiso J. Identification of C-terminal fragments of  $\alpha$ - and  $\beta$ -tubulin in amyloid deposits of the familial cerebral amyloid angiopathy, British type. *BiochemicalBiophysical Research Communications* 1996; 219: 238-242.
42. Baumann MH, Golabek A, Lalowski, **Wisniewski T**. Micropreparative gel electrophoresis of small molecular weight peptides: purification of highly insoluble amyloid peptide fragments. *Analytical Biochemistry* 1996, 236: 191-198.

43. Soto C, Golabek A, **Wisniewski T**, Castano EM. Alzheimer's soluble  $\beta$ -amyloid is conformationally modified by apolipoprotein E in vitro. *Neuroreport* 1996, 7: 721-725.
44. Palha JA, Moreira P, **Wisniewski T**, Frangione B, Sariava MJ. Transthyretin gene in Alzheimer's disease patients. *Neuroscience Letters* 1996; 204: 212-214.
45. Golabek A, Soto C, Vogel T, **Wisniewski T**. The interaction between apolipoprotein E and Alzheimer's amyloid  $\beta$ -peptide is dependent on  $\beta$ -peptide conformation. *The Journal of Biological Chemistry* 1996; 271: 10602-10606.
46. Lemere CA, Blusztajn JK, Yamaguchi H, **Wisniewski T**, Saido T, Selkoe D. Sequence of deposition of heterogeneous amyloid  $\beta$ -peptides and apo E in Down syndrome: implications for initial events in amyloid plaque formation. *Neurobiology of Disease* 1996; 3:16-32.
47. Vidal R, Ghiso J, **Wisniewski T**, Frangione B. Alzheimer's presenilin 1 gene expression in platelets and megakaryocytes: Identification of a novel splice variant. *FEBS Letters* 1996; 393: 19-23.
48. Garzuly F, **Wisniewski T**, Brittig F, Budka H. Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). *Neurology*, 47: 1562-1567, 1996.
49. Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B, **Wisniewski T**. The "non-amyloidogenic" p3 fragment (amyloid  $\beta$  17-42) is a major constituent of Down syndrome cerebellar preamyloid. *Journal of Biological Chemistry*, 271: 33623-33631, 1996.
50. Palha JA, Moreira P, **Wisniewski T**, Frangione B, Saraiva MJ. C for T substitution at codon 108: the first identified silent mutation in the transthyretin gene. *Amyloid: International Journal of Experimental Clinical Investigation*, 4:52-53, 1997.
51. Ghiso J, Calero M, Matsubara E, Governale S, Chuba J, Beavis R, **Wisniewski T**, Frangione B. Alzheimer's soluble amyloid  $\beta$  is a normal component of human urine. *FEBS Letters*, 408: 105-108, 1997.
52. **Wisniewski T**, Dowjat W, Permanne B, Palha J, Kumar A, Gallo G, Frangione B. Presenilin is associated with Alzheimer's disease amyloid. *American Journal of Pathology*, 151: 601-610, 1997.
53. Permanne B, Perez C, Soto C, Frangione B, **Wisniewski T**. Detection of apolipoprotein E/dimeric soluble amyloid  $\beta$  complexes in Alzheimer's disease brain

supernatants. *Biochem. Biophys. Res. Commun.*, 240: 715-720, 1997.

54. **Wisniewski T**, Dowjat WK, Buxbaum JD, Khorhova O, Efthimiopoulos S, Kulczycki J, Lojkowska W, Wegiel J, Wisniewski HM, Frangione B. A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years. *NeuroReport*, 9: 217-221, 1998.
55. K.E. Wisniewski, N.Zhong, W. Kaszmarski, A. Kaszmarski, E. Kida, W.T. Brown, K.O. Schwartz, E.S. Stenroos, A.M. Lazzarini, A.J. Rubin, W.G. Johnson, **T.M. Wisniewski**. Compound heterozygous genotype is associated with protracted juvenile neuronal ceroid lipofuscinosis. *Annals of Neurology*, 43: 106-110, 1998.
56. Askanas V, King Engel W, Chih-Chao Y, Alvarez R B, Lee VMY, **Wisniewski T**. Light and electron microscopic immunolocalization of presenilin I in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal recessive inclusion body myopathy. *American Journal of Pathology*, 152: 889-895, 1998.
57. **Wisniewski T**, Goldman JE.  $\alpha$ B-Crystallin is associated with intermediate filaments in astrocytoma cells. *Neurochemistry Research*, 23: 389-396, 1998.
58. Wegiel J, Wisniewski HM, Izabela K, Michal T, Eulalia B, Eirene P, Jerzy K, Wieslaw D, **Wisniewski T**. Cell-type specific enhancement of amyloid  $\beta$  deposition in a novel presenilin-1 mutation (P117L). *Journal of Neuropathology and Experimental Neurology*, 57: 831-838, 1998.
59. Pomara N, Shao B, **Wisniewski T**, Mehta PD. Decreases in plasma A $\beta$  1-40 levels with aging in non-demented elderly with apoE-epsilon 4 allele. *Neurochemistry Research*, 23: 1563-1566, 1998.
60. Efthimiopoulos S, Floor E, Georgakopoulos A, Shior J, Cui W, Yasothornsrikul S, Hook VYH, **Wisniewski T**, Buee L, Robakis NK. Enrichment of Presenilin 1 peptides in neuronal large dense core and somatodendritic clathrin coated vesicles. *Journal of Neurochemistry*, 71: 2365-2372, 1998.
61. Copp RP, **Wisniewski T**, Hentati F, Larnaout A, Hamida MB, Kayden HJ. Localization of  $\alpha$ -tocopherol transfer protein in the brains of patients with ataxia with vitamin E deficiency and other oxidative stress related neurodegenerative disorders. *Brain Research*, 822: 80-87, 1999.
62. Aucouturier P, Kascak RJ, Frangione B, **Wisniewski T**. Biochemical and conformational variability of human prion strains in sporadic Creutzfeldt-Jakob disease. *Neuroscience Letters*, 274(1):33-36, 1999.

63. Dowjat WK, **Wisniewski T**, Efthimiopoulos S, Wisniewski HM. Inhibition of neurite outgrowth by Familial Alzheimer's disease linked presenilin-1 mutations. *Neuroscience Letters*, 267: 141-144, 1999.
64. Stoltner, SE, Grenfell TJ, Mori C, Wisniewski KE, **Wisniewski TM**, Selkoe DJ, Lemere CA. Temporal accrual of complement proteins in amyloid plaques in Down syndrome with Alzheimer's disease. *American Journal of Pathology*, 156: 489-499, 2000.
65. Soto C, Kascsak RJ, Saborio GP, Aucouturier P, **Wisniewski T**, Prelli F, Kascsak R, Mendez E, Kumar A, Harris DA, Ironside J, Tagliavini F, Carp RI, Frangione B. Reversion of prion protein conformational changes by synthetic  $\beta$ -sheet breaker peptides. *The Lancet*, 355: 192-197, 2000.
66. Sigurdsson EM, Permanne B, Soto C, **Wisniewski T**, Frangione B. In Vivo Reversal of Amyloid  $\beta$  Lesions in Rat Brain, *Journal of Neuropathology and Experimental Neurology*, 59: 11-17, 2000.
67. Golabek AA, Kida E, Walus M, Perez C, **Wisniewski T**, Soto C. Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid  $\beta$ -peptide with the N-terminal, receptor binding domain of apolipoprotein E. *Biophysical Journal*, 79: 1008-1015, 2000.
68. Ji Y, Permanne B, Sigurdsson EM, Holtzman DM, **Wisniewski T**. Amyloid  $\beta$ 40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. *Journal of Alzheimer's Disease*, 3: 23-30, 2001.
69. Poeggeler, B, Miravalle, L, Zagorski M, **Wisniewski T**, Chyan YJ, Zhang Y, Shao H, Bryant-Thomas T, Vidal R, Frangione B, Ghiso J, Pappolla MA. Melatonin reverses the pro-fibrillogenic effects of apolipoprotein E4 on the Alzheimer's  $\beta$ -amyloid protein. *Biochemistry*, 40: 14995-15001, 2001.
70. Dowjat WK, Wisniewski H, **Wisniewski T**. Alzheimer's disease presenilin-1 expression modulates the assembly of neurofilaments. *Neuroscience*, 103: 1-8, 2001.
71. Kulczycki J, Bertrand E, Lojkowska W, Dowjat W, **Wisniewski T**, Lyxzywek-Zwierz M. Familial Alzheimer's disease connected with a mutation in presenilin gene 1. *Neurologia I Neurochirurgia Polska*, 35: 213-224, 2001.
72. Aucouturier P, Geissmann F, Saborio G, Meeker HC, Damotte D, Kascsak R, Kascsak R, Carp RI, **Wisniewski T**. Scrapie neuroinvasion in RAG-1<sup>0/0</sup> mice by transfer of infected splenic dendritic cells. *Journal of Clinical Investigation*, 108: 703-708,

2001.

73. Wegiel J, Bobinski M, Tarnawski M, Dziwiatowski J, Popovitch E, Miller DC, **Wisniewski T**, Golomb J, de Leon MJ, Reisberg B. Fibrillar amyloid- $\beta$  affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration. *Acta Neuropathology* 101: 585-590, 2001.
74. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, **Wisniewski T**. Immunization with a non-toxic/non-fibrillar amyloid- $\beta$  homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. *American Journal of Pathology*, 159: 439-447, 2001.
75. Wen PH, Shao X, Shao Z, Hof PR, **Wisniewski T**, Kelley K, Friedrich VL, Ho L, Painetti GM, Robakis NK, Elder GA. Overexpression of wild type but not an FAD mutant presenilin-1 promotes hippocampal neurogenesis in adult mice, *Neurobiology of Disease*, 10: 8-19, 2002.
76. Mori C, Spooner ET, Wisniewski KE, **Wisniewski TM**, Yamaguchi H, Saido TC, Li C, Tolan DR, Selkoe DJ, Lemere CA. Intraneuronal A $\beta$ 42 accumulation in Down syndrome brain. *Amyloid*, 9:88-102, 2002.
77. Wang ZH, Ji Y, Zeng B, Raksadawan N, Pastores GM, Ong E, **Wisniewski T**, Kolodny EH. Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model with Parkinson's disease. *Neuroscience*, 113: 629-640, 2002.
78. Mackic JB, Bading J, Ghiso J, Walker L, **Wisniewski T**, Frangione B, Zlokovic BV. Transport across the blood-brain barrier and differential cerebrovascular sequestration of circulating Alzheimer's amyloid- $\beta$  peptide in aged Rhesus vs. aged Squirrel monkeys. *Vascular Pharmacology*, 38: 303-313, 2002.
79. Poduslo JF, Wengenack TM, Curran GL, **Wisniewski T**, Sigurdsson E, Macura SI, Borowski BJ, Jack CR. Molecular contrast enhanced magnetic resonance imaging of Alzheimer's amyloid plaques. *Neurobiology of Disease*, 11: 315-329, 2002.
80. De Leon MJ, Segal S, Tarshish C, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, Saint Louis LA, DeBarnardis J, Kerkmanand D, Qadri F, Gary A, Lesbre, **Wisniewski T**, Poirier J, Davies P. Longitudinal Tau levels increase in mild cognitive impairment. *Neuroscience Letters*, 333: 183-186, 2002.
81. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Wen P, Efthimiopoulos S, **Wisniewski T**, Robakis NK. A presenilin-1 mediated  $\gamma$ -secretase activity cleaves cadherins and controls disassembly of adherens

- junctions. *EMBO Journal*, 21: 1948-1956, 2002.
82. Wegiel J, Kuchna I, **Wisniewski T**, de Leon MJ, Reisberg B, Pirttila T, Kivimaki T, Lehtimaki. Vascular fibrosis and calcification in the hippocampus in aging, Alzheimer's disease and Down syndrome. *Acta Neuropathologica*, 103: 333-343, 2002.
  83. Sigurdsson E, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, **Wisniewski T**. Vaccination delays the onset of prion disease in mice. *American Journal of Pathology*, 161: 13-17, 2002.
  84. Wong BS, Li R, Sassoon J, Liu T, Pan T, Kang SC, **Wisniewski T**, Brown DR, Sy MS. Mapping the antigenicity of copper-treated cellular prion protein with the scrapie isoform. *Cellular and Molecular Life Sciences*, 60: 1224-1234, 2003.
  85. Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, Carp RI, Meeker HC, Frangione B, **Wisniewski T**. Anti-PrP antibodies for prophylaxis following prion exposure. *Neuroscience Letters*, 336: 185-187, 2003.
  86. Zaim Wadghiri Y, Sigurdsson EM, Sadowski M, Elliot JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, **Wisniewski T\***, Turnbull DH\* (\*joint senior authors). Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance micro-imaging. *Magnetic Resonance in Medicine*, 50: 293-302, 2003.
  87. Ji Y, Gong Y, Gan W, Beach T, Holtzman DM, **Wisniewski T**. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. *Neuroscience*, 122: 305-315, 2003.
  88. Sadowski M, Tang CY, Aguinaldo G, Carp R, Meeker HC, **Wisniewski T**. *In vivo* magnetic resonance imaging signal changes in scrapie infected mice. *Neuroscience Letters*, 345: 1-4, 2003.
  89. Sigurdsson EM, Brown D, Alim MA, Scholtzova H, Carp R, Meeker HC, Prelli F, Frangione B, **Wisniewski T**. Copper chelation delays the onset of prion disease. *Journal of Biological Chemistry*, 278: 46199-46202, 2003.
  90. Kang SC, Brown DR, Whiteman M, Li R, Pan T, Perry G, **Wisniewski T**, Sy MS, Wong BS. Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie infected mice. *Journal of Pathology*, 203: 603-608, 2004.
  91. Pan T, Li R, Kang SC, Wong BS, **Wisniewski T**, Sy MS. Epitope scanning reveals gain and loss of strain specific antibody binding epitopes associated with the

- conversion of normal cellular prion to scrapie prion. *Journal of Neurochemistry*, 90: 1205-1217, 2004.
92. Wegiel J, Kuchna I, Novicki K, Dowjat K, Reisberg B, DeLeon M, **Wisniewski T**, Chen-Hwang MC, Hwang YW. Cell type and brain structure specific patterns of distribution of minibrain kinase in human brain. *Brain Research*, 1010: 69-80, 2004.
  93. Dowjat WK, Kuchna I, **Wisniewski T**, Wegiel J. A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (P117S): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. *Journal of Alzheimer's Disease*, 6: 31-43, 2004
  94. Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen C, Duff K, Nixon RA, Gruen RJ, **Wisniewski T**. Decreased hippocampal glucose metabolism correlates with neuronal loss and impaired recall in Alzheimer's disease model mice. *Journal of Neuropathology and Experimental Neurology*, 63: 418-428, 2004.
  95. Sadowski M, Pankiewicz J, Scholtzova H, Li Y, Quartermain D, Duff K, **Wisniewski T**. Links between the pathology of Alzheimer's disease and vascular dementia. *Neurochemical Research*, 29: 1251-1260, 2004.
  96. Helpert JA, Falangola MF, Dyakin VV, Lee SP, Bogart A, Estok K, Ardekani B, Duff K, Branch C, **Wisniewski T**, De Leon MJ, Wolf O, O'Shea J, Wegiel J, Nixon RA. Magnetic resonance imaging assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. *Magnetic Resonance in Medicine*, 51: 794-798, 2004.
  97. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, **Wisniewski T**. Blocking the apolipoprotein E/  $\beta$ -amyloid interaction reduces  $\beta$ -amyloid toxicity and decreases  $\beta$ -amyloid load in transgenic mice. *American Journal of Pathology*, 165: 937-948, 2004.
  98. Sigurdsson EM, Knudsen E, Asuni A, Sage D, Goni F, Quartermain D, Frangione B, **Wisniewski T**. Enhanced cognition with a reduced immune response in an AD mouse model immunized with A $\beta$  derivatives. *Journal of Neuroscience*, 24: 6277-6282, 2004.
  99. Sadowski M, Pankiewicz J, Scholtzova H, Tsai J, Li Y, Carp RI, Meeker HC, Gambetti P, Debnath M, Mathis CA, Li S, Gan WB, Klunk WE, **Wisniewski T**. Targeting prion amyloid deposits in vivo using methoxy-X04, *Journal of Neuropathology*

*and Experimental Neurology*, 63: 775-784, 2004.

100. Pan T, Wong P, Chang B, Li C, Li R, Kang SC, **Wisniewski T**, Sy MS. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease. *Journal of Virology*, 79: 934-943, 2005
101. Goni F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, Carp R, Meeker HC, Brown DR, Chabalgoity JA, Sigurdsson EM, **Wisniewski T**. Mucosal vaccination delays or prevents prion infection via an oral route. *Neuroscience*, 133: 413-421, 2005.
102. Pan T, Chang B, Wong P, Li C, Li R, Kang SC, Thompsett AR, Po T, Yin S, Barnard G, McConnell I, Brown DR, **Wisniewski T**, Sy MS. An aggregate specific ELISA: Detection of conformational differences between recombinant PrP protein dimers and PrP<sup>Sc</sup> aggregates. *Journal of Virology*, 79: 12355-12364., 2005.
103. Pankiewicz J, Prelli F, Sy MS, Kascsak RJ, Kascsak RB, Spinner DS, Carp RI, Meeker HC, Sadowski M, **Wisniewski T**. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. *European Journal of Neuroscience*, 23: 2635-2647, 2006.
104. Leal MC, Dorfman VB, Gamba GF, Frangione B, **Wisniewski T**, Castano EM, Sigurdsson EM, Morelli L. Plaque-Associated Overexpression of Insulin-Degrading Enzyme in the Cerebral Cortex of Aged Transgenic Tg2576 Mice With Alzheimer Pathology. *Journal of Neuropathology and Experimental Neurology*, 65: :976-987, 2006.
105. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Wen P, Quartermain D, **Wisniewski T**. Blocking the Apolipoprotein E/Amyloid- $\beta$  Interaction as a Potential Therapeutic Approach for Alzheimer's Disease. *Proceedings of the National Academy of Science*, 49: 18787-18792, 2006.
106. Asuni A, Boutajangout A, Scholtzova H, Knudsen E, Li Y, Quartermain D, Frangione B, **Wisniewski T**, Sigurdsson EM. A $\beta$  derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. *European Journal of Neuroscience*, 24: 2530-2542, 2006.
107. Chang B, Cheng X, Yin S, Pan T, Zhang H, Wong P, Kang SC, Xiao F, Yan H, Li C, Wolfe LL, Miller MW, **Wisniewski T**, Greene MI, Sy MS. A blood test for prion: disease associated prion aggregates detected in the blood of infected but asymptomatic animals. *Clinical and Vaccine Immunology*, 14: 36-43, 2007

108. Spinner DS, Kascsak RB, LaFauci G, Meeker HC, Xuemin Y, Flory MJ, Kim JI, Schuller-Levis GB, Levis WR, **Wisniewski T**, Carp RI, Kascsak RJ. CpG Oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrP<sup>Sc</sup> in mice immunized with 139A scrapie-associated fibrils. *Journal of Leukocyte Biology*, 14(1):36-43, 2007
109. Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Mazur-Kolecka B, Imaki H, Wegiel J, Mehta PD, Silverman WP, Reisberg B, deLeon M, **Wisniewski T**, Pirttilla T, Frey H, Lehtimaki T, Kivimaki T, Visser FE, Kamphorst W, Potempska A, Bolton D, Currie JR, and Miller DL. Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. *Acta Neuropathologica (Berl)*, 113(4):389-402, 2007
110. Litterst C, Georgakopoulos A, Shioi J, Ghersi E, **Wisniewski T**, Wang R, Ludwig A, Robakis NK. Ligand binding and calcium influx induce distinct ectodomain/γ-secretase processing pathways of EPHB2 receptor. *Journal of Biological Chemistry* 282(22):16155-63, 2007.
111. Webb S, Lekishvili T, Loeschner C, Sellarajah S, Prelli F, **Wisniewski T**, Gilbert IM, Brown DR. Mechanistic insights into prion curing by novel anti-prion compounds. *Journal of Virology*, 81: 10729-10741, 2007.
112. Li Q, Min J, Namm J, Kim EM, Ji Y, Wu H, **Wisniewski T**, Chang YT. Styryl based in vivo imaging agents for β-amyloid plaques. *ChemBioChem*, 8(14): 1679-1687, 2007.
113. Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alsheklee A, Castellani R, Cohen M, Marder K, Harris C, Montine T, **Wisniewski T**, Dickson DW, Hulette CM, DeArmond SJ, Mastrianni JA, Kong Q, Zou WQ. A novel human prion disease with protease-sensitive prion. *New England Journal of Medicine*, in press.
114. Firuzi O, Zhuo J, Chinnici CM, **Wisniewski T**, Pratico D. 5-lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer's disease. *FASEB Journal*, In press.
115. Sigurdsson EM, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, Asuni A, Tsui WH, Sadowski M, Turnbull DH, de Leon M, **Wisniewski T**. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. *Neurobiology of Aging*, in press.

**Books, Chapters in Books, Letters and Reviews:**

1. Post K, Onesti S, **Wisniewski T**. Pituitary Apoplexy. In Intracranial Hemorrhages: Etiology, Pathogenesis, Clinical Features and Treatment. Editor Kauffman H. Raven Press; 1991
2. **Wisniewski T.M.**, Wisniewski HM. Alzheimer's Disease and the Cerebral Amyloidoses. In Neurodevelopment, Aging and Cognition. Editors Ivica Kostovic, Stevo Knezevic, Henry M. Wisniewski and George J. Spilich, Birkhauser, Boston ; p157-172; 1992.
3. Frangione B, Haltia M, Levy E, Ghiso J, Kiuru S, Prelli F, **Wisniewski T**. Familial amyloidosis- Finnish type- and its relationship to Lewy bodies in Parkinson's and Diffuse Lewy Body disease. In the Proceedings of the XIth International Congress of Neuropathology- Kyoto; p150-156; 1992.
4. **Wisniewski T**, Haltia M, Ghiso J, Frangione B. I corpi di Lewy immunoreagiscono con gli anticorpi dell-amiloide di tip Finnico omologo alla gelsolina. *Update on Parkinson's disease and migraine* 1992: 2:59-60.
6. **Wisniewski T**, Frangione B. Aberrant aggregation of a normal amyloid precursor protein fragment. *Neuroscience Facts* 1992; 3:66.
7. Frangione B, **Wisniewski T**, Tagliavini F, Bugiani O, Ghiso J. Alzheimer's disease and Dutch variant: "Opposing faces of a single coin." In Alzheimer's Disease: Advances in Clinical and Basic Research. Editors: Corain B, Iqbal K, Nicolin M. Wiley; p:387-396;1993.
8. Frangione B, **Wisniewski T**, Ghiso J. Alzheimer's disease and amyloid  $\beta$ . In Amyloid and Amyloidosis 1993. Ed.:Kiselevsky R, Benson MD, Frangione B, Gaudie J, Muckle TJ, Young ID. Parthenon Publishing, 1994; pp:310-315.
9. Ghiso J, **Wisniewski T**, Frangione B. Unifying features of systemic and cerebral amyloidoses. *Molecular Neurobiology* 1994; 8: 49-64.
10. Frangione B, **Wisniewski T**, Ghiso J. Position Paper on Alzheimer's Disease Research. *Neurobiology of Aging* 1994; 15 (suppl 2):S97-S99.
11. Frangione B, **Wisniewski T**, Castano E, Ghiso J. Amyloids, Genes and Chaperones. In Research Advances in Alzheimer's Disease and Related Disorders. Ed. Iqbal K., Mortimer JA, Winblad B, Wisniewski T. Publisher John Wiley, Chapter 61, pp:563-568; 1995.

12. Zlokovic, B., Mackic, J., Martel, C., **Wisniewski, T.**, Frangione, B., and Ghiso, J.: The blood brain barrier regulates transport of Alzheimer's amyloid  $\beta$  and apolipoproteins E and J. In K. Iqbal, J. Mortimer, B. Winblad and H. Wisniewski (eds.) Research advances in Alzheimer's disease and related disorders. Proceedings of the IV international conference on Alzheimer's disease and related disorders. Minneapolis, July/August, 1994. John Wiley & Sons, Chichester (England), 1995, pp 585-595.
13. **Wisniewski T**, Frangione B. The molecular biology of brain aging and neurodegenerative disorders. *Acta Neurobiologiae Experimentalis* 1996; 56: 267-279.
14. **Wisniewski T**, Frangione B. Apolipoprotein E, Amyloidosis and Alzheimer's Disease. *Dementia (Japan)* 1996; 10: 171-183.
15. Frangione B, Castano EM, **Wisniewski T**, Ghiso J, Prelli F, Vidal R. Apolipoprotein E and amyloidosis. *Ciba Foundation Symposium* 1996; 199: 132-141.
16. Frangione B, Castano EM, Prelli F, Soto C, Ghiso J, **Wisniewski T**. Chaperoning Amyloid in Alzheimer's Disease: The Art of Avoiding Sticky Situations? In: A.D.Roses, K.H. Weisgraber and Y.Christen (ed.) Apolipoprotein E and Alzheimer's Disease; Springer-Verlag, Berlin, Heidelberg, 1996; pp: 151-160.
17. **Wisniewski T**, Ghiso J, Frangione B. Alzheimer's Disease and Amyloid  $\beta$ . *Neurobiology of Disease* 1997; 4: 313-328.
18. **Wisniewski T**, Dowjat K, Frangione B. The Prionoses and Other Conformational Disorders. *Amyloid: The International Journal of Experimental and Clinical Investigation* 1998; 5: 212-224.
19. Wisniewski HM, Wegiel J, **Wisniewski T**. Pathogenesis of amyloid- $\beta$  plaques: activated microglia the cause of fibrillar amyloid formation and neuropil degeneration. *NeuroScience News* 1998; 1: 30-34.
20. Lalowski M, Baumann M, Rauvala H, Frangione B, **Wisniewski T**. HB-GAM, a novel amyloid associated protein, is present in prion related disorders and other cerebral amyloidoses. In: Fischer et al. (Editors) Progress in Alzheimer's and Parkinson's Diseases; Plenum Press, New York, 1998; pp: 121-131.
21. Aucoeurier, P, Frangione B, **Wisniewski T**. Prion Diseases and the Immune System. *Annals of Internal Medicine* (Paris, France), 1999; 150: 75-78.

22. **Wisniewski T**, Frangione B. Amyloid: Chemical and Molecular Considerations. In: M. DeLeon (Ed.) An Atlas of Alzheimer's Disease. Parthenon Publishing, Carnforth, U.K., 1999; pp:109-130.
23. Aucouturier P, Carp RI, Carnuad C, **Wisniewski T**. Prion Disease and the Immune System. *Clinical Immunology*, 2000, 96: 79-85.
24. **Wisniewski T**, Frangione B. Book Review of *Prion Biology and Diseases*, Edited by Stanley B. Prusiner. *New England Journal of Medicine*, 2000, 342:983.
25. Kayden HJ, **Wisniewski T**. On the biological activity of Vitamin E. *American Journal of Clinical Nutrition*, 2000, 72: 201-202.
26. **Wisniewski T**. Henry M. Wisniewski, A life history. *Journal of Alzheimer's Disease*, 2001, 3: 7-22.
27. **Wisniewski T**, Sigurdsson EM, Aucouturier P, Frangione B. Chapter 13: Conformation as a Therapeutic Target in the Prionoses and other Neurodegenerative Conditions. In Baker HF (ed.) Molecular and Cellular Pathology in Prion Diseases. The Humana Press, Inc.(Totowa, NJ) p: 223-236, 2001.
28. **Wisniewski T**. Prion Related Diseases. In Lorenzo NY (ed.) eMedicine Neurology. <http://www.emedicine.com/neuro/topic662.htm>, 2002
29. Sigurdsson EM, Frangione B, **Wisniewski T**. A safer vaccine for Alzheimer's disease? *Neurobiology of Aging*, 23: 1001-1008, 2002.
30. **Wisniewski T**, Brown D, Sigurdsson EM. Therapeutics in Alzheimer's and Prion Diseases. *Biochemical Society Transactions*, 30: 574-578, 2002.
31. Sigurdsson EM, Frangione B, **Wisniewski T**. Immunization for Alzheimer's Disease. *Drug Development Research*, 56: 135-142, 2002.
32. Sigurdsson EM, **Wisniewski T**, Frangione B. Infectivity of Amyloid Diseases. *Trends in Molecular Medicine*, 8: 411-413, 2002.
33. **Wisniewski T**, Sigurdsson EM. Immunization Treatment Approaches in Alzheimer and Prion Diseases. *Current Neurology and Neuroscience Reports*, 2: 400-404, 2002.
34. Wegiel J, **Wisniewski T**, Reisberg B, Silverman W. Alzheimer dementia neuropathology. In: Dementia. Presentations, differential diagnosis, and nosology. Edited by V. Olga B. Emery, PhD. and Thomas E. Oxman, MD., The Johns Hopkins University Press, Baltimore and London, Chapter 4: 89-120, 2003.

35. Sadowski M, **Wisniewski T**. Immunological treatment and imaging approaches for prion disease. *Current Medical Chemistry: Immunology, Endocrine & Metabolic Agents*, 3: 113-118, 2003.
36. Sadowski M, Verma A, **Wisniewski T**. Prion Diseases. In Neurology in Clinical Practice, 4<sup>th</sup> Edition, Bradley W. (ed.), Chapter 59G: 1613-1630, 2004.
37. Sigurdsson EM, Wadghiri YZ, Sadowski M, Elliot JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Duff K, Turnbull DH, **Wisniewski T**. In vivo magnetic resonance of amyloid plaques in Alzheimer's disease model mice. Chapter in: *The Living Brain and Alzheimer's Disease*, Fondation IPSEN. Pages: 47-59, Ed. Hyman B., Springer Verlag Berlin Heidelberg, 2004.
38. **Wisniewski T**, Sadowski M. Book title: 100 Questions and Answers about Alzheimer's disease. Jones and Bartlett Publishers, 2004.
39. Sadowski M, **Wisniewski T**. Vaccines for Conformational Disorders. *Expert Review of Vaccines*, 3 (3): 279-290, 2004.
40. **Wisniewski T**. Mad cow disease and variant Creutzfeldt-Jakob disease. In Lorenzo NY (ed.) eMedicine Neurology. <http://www.emedicine.com/neuro> , 2004.
41. Ghiso J, **Wisniewski T**. An animal model of vascular amyloidosis. *Nature Neuroscience*, 7: 902-904, 2004.
42. Sasson J, Sadowski M, **Wisniewski T**, Brown DR. Therapeutics and prion disease: can immunization or drugs be effective? *Mini-Reviews in Medicinal Chemistry*, 5: 361-366, 2005.
43. Wadghiri YZ, Sigurdsson EM, **Wisniewski T**, Turnbull DH. MR Imaging of Amyloid Plaques in Transgenic Mice. Chapter 27, pages: 365-380; In Sigurdsson EM (ed) *Amyloid Proteins: Methods in Molecular Biology* Vol. 299, Humana Press Inc., Totowa, NJ, 2005.
44. **Wisniewski T**, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. *Brain Pathology*, 15: 72-77, 2005.
45. **Wisniewski T**. Is amyloid-beta-peptide immunization clinically effective in patients with Alzheimer's disease? *Nature Clinical Practice Neurology*. 1: 84-85, 2005.
46. Sigurdsson E., **Wisniewski T**. Promising Developments in Prion Immunotherapy. *Expert Reviews of Vaccines*, 4: 607-610, 2005.

47. **Wisniewski T.**, Sigurdsson E. Prion Related Diseases. In Lorenzo NY (ed.) eMedicine Neurology. <http://www.emedicine.com/neuro/topic662.htm>, 2006
48. Sadowski M, **Wisniewski T.** Apolipoproteins in different amyloidoses. In *Protein Misfolding. Aggregation and Conformational Diseases*. Editors: Uversky VN, Fink AL; Kluwer Academic/Plenum Publishers. Chapter 16, pages: 329-350, 2006.
49. Sadowski M, **Wisniewski T.** Disease modifying approaches for Alzheimer's pathology. *Current Pharmaceutical Design* 13(19):1943-54, 2007.
50. **Wisniewski T**, Chabalgoity J.A. & Goni F. Is vaccination against transmissible spongiform encephalopathy feasible? In *Animal vaccination – Part 1: development, production and use of vaccines* (P.-P. Pastoret, M. Lombard & A.A. Schudel, eds). *Rev. sci. tech. Off. int. Epiz.*, 26 (1), 243-251, 2007.
51. Sadowski M, Verma A, **Wisniewski T.** Prion Diseases. In Neurology in Clinical Practice, 5<sup>th</sup> Edition, Bradley W. (ed.), Chapter 57F, In press.
52. Sigurdsson E., **Wisniewski T.** Therapeutic Approaches for Prion and Alzheimer's Diseases. *FEBS Journal*, 274: 3784-3798, 2007.

**Total of 167 Full length publications**